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ABSTRACT
Background Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-
stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause. Characterizing the 
cost–utility (cu) of this therapy could help to determine its role in clinical practice.
Methods Using the perspective of the Canadian health care system, we examined the cu of adjuvant endocrine 
therapy with or without za in women with early-stage endocrine-sensitive breast cancer and lle. A Markov model was 
used to compute the cumulative costs in Canadian dollars and the quality-adjusted life-years (qalys) gained from 
each adjuvant strategy, discounted at a rate of 5% annually. The model incorporated the dfs and fracture benefits 
of adjuvant za. Probabilistic and one-way sensitivity analyses were conducted to examine key model parameters.
Results Compared with a no-za strategy, adjuvant za in the induced and natural menopause groups was associated 
with, respectively, $7,825 and $7,789 in incremental costs and 0.46 and 0.34 in qaly gains for cu ratios of $17,007 and 
$23,093 per qaly gained. In one-way sensitivity analyses, the results were most sensitive to changes in the za dfs 
benefit. Probabilistic sensitivity analysis suggested a 100% probability of adjuvant za being a cost-effective strategy 
at a threshold of $100,000 per qaly gained.
Conclusions Based on available data, adjuvant za appears to be a cost-effective strategy in women with endocrine-
sensitive breast cancer and lle, having cu ratios well below accepted thresholds.
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INTRODUCTION
More than 50% of breast cancer patients present with early-
stage endocrine-sensitive disease. In that group, breast 
cancer outcomes have improved significantly over time 
partly because of increasingly efficacious adjuvant thera-
pies1. Based on favourable preclinical data2, mitigation of 
therapy-related bone density loss in the adjuvant setting3–5, 
and prevention of skeletal events in the metastatic setting6, 
the intravenous bisphosphonate zoledronic acid (za) has 
been investigated as an adjuvant therapy for breast cancer.
Marked methodologic heterogeneity has complicated 
the interpretation of trials examining adjuvant za in early 
breast cancer. Many of the completed trials investigated 
adjuvant bisphosphonate therapy for its effect on bone 
health7–12. Those trials often compared early with delayed 
bisphosphonate therapy rather than adjuvant za with no 
bisphosphonate, or considered primary endpoints that 
were unrelated to breast cancer outcomes. The only two 
phase iii trials that considered cancer-specific primary 
endpoints and compared adjuvant therapy with and with-
out za (abcsg-12 and azure) independently suggested that 
adjuvant za improves breast cancer outcomes in patients 
with low circulating estrogen levels secondary to induced 
or natural menopause13,14. Meta-analyses of adjuvant za 
and adjuvant bisphosphonate trials as a whole appear to 
confirm the benefit in that subgroup of patients6,15–17.
In many jurisdictions, the adoption of adjuvant za 
into routine clinical practice will depend on its “value for 
money” in addition to its clinical benefit. To further inform 
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treatment and regulatory decisions, we performed a cost–
utility (cu) analysis of the incremental cost per quality-
adjusted life-year (qaly) gained associated with adjuvant 
za in patients with early-stage endocrine-sensitive breast 
cancer and low levels of estrogen (lle).
METHODS
Cohort
Our study examined two hypothetical cohorts of women 
undergoing adjuvant therapy after initial surgical resection 
of early-stage endocrine-sensitive breast cancer. The first 
cohort (induced menopause) assumed an average age of 
40 years and included women treated with adjuvant ovar-
ian suppression using a luteinizing-hormone releasing-
hormone agonist for 3 years, as in the abscg-12 trial13. 
Adjuvant tamoxifen was given concurrently for a total of 
5 years. The second cohort (natural menopause) assumed 
an average age of 60 years and included postmenopausal 
women treated with adjuvant endocrine therapy for a total 
of 5 years.
In the induced menopause group, adjuvant endocrine 
therapy consisted of tamoxifen (because the aromatase 
inhibitor arm was not superior to tamoxifen in the abscg-12 
trial13). The distribution of adjuvant endocrine therapy in 
the natural menopause group was based on expert opinion 
representing common Canadian practice.
Markov Model
The analysis took a Markov approach by defining a num-
ber of possible health states and modelling the probability 
of transition from one state to another in monthly cycles 
(Figure 1). The model was developed in Excel (Microsoft 
Corporation, Redmond, WA, U.S.A.) to examine the cu 
of adjuvant za in addition to endocrine therapy (“za 
strategy”) relative to adjuvant endocrine therapy alone 
(“no-za strategy”).
In the primary analysis, za was given per the azure 
schedule (4 mg by intravenous infusion every 1 month for 
6 doses, followed by every 3 months for 8 doses, followed 
by every 6 months for 5 doses)14. Cumulative costs and 
outcomes associated with each strategy were determined 
over a defined number of cycles, reflecting a lifetime ho-
rizon. Costs and outcomes were both discounted by 5% 
annually. The analysis reported per-patient cumulative 
and incremental costs in Canadian dollars and outcomes 
in qalys gained. The cu was then expressed as the cost per 
qaly gained—that is, the incremental cu ratio (icur)—for 
a za strategy compared with a no-za strategy. The analysis 
took a probabilistic approach and used 5000 iterations 
per cohort to estimate the uncertainty related to costs 
and effects.
Health States
The model incorporated 7 distinct health states (Figure 1). 
All patients entered the model in the “On therapy” state 
after surgical resection and could transition to other states 
based on event rates derived from the literature and de-
scribed in the Event Rates subsection (next). Only patients 
treated with za could transition into the “Osteonecrosis of 
the jaw” state18. All patients were subject to state-specific 
and age-specific background mortality based on Canada 
life tables19.
Event Rates
Table i shows key model parameters. The risks of recurrence 
in the absence of adjuvant systemic therapy over model 
years 0–15 was derived from the Early Breast Cancer Trial-
ists’ Collaborative Group meta-analysis1. The specific risk 
in each year was modelled using a beta distribution, but 
the resulting lifetime risk was nonparametric. The relative 
dfs benefit with the addition of adjuvant za to endocrine 
therapy was pooled from the abcsg-12 and azure trials 
(Table i)6. The primary analysis assumed no carryover 
benefit for adjuvant za beyond the 5 years of therapy.
Osteonecrosis of the jaw necessitating discontinu-
ation of za developed in 1.6% of the patients in azure 
(Table i)18. Of those patients, 46% required minor surgical 
procedures25. Although no other specific adverse effects 
were modelled, adjuvant za was assumed to be associated 
with a small utility deficit applied uniformly during za 
therapy (Table ii).
Baseline fracture rates and the anatomic distribution 
of fractures were estimated from the trials of adjuvant 
endocrine therapies in the relevant setting (Table i)13,21–24. 
The reduction in fracture risk associated with za therapy 
was based on abcsg-12 in the induced menopause cohort 
(hazard ratio: 0.71) and the published literature in the 
natural menopause cohort (hazard ratio: 0.65)6,13.
For other parameters that did not vary between the 
treatment strategies, please refer to our previously pub-
lished work26,27. Table iii shows a list of model assumptions.
FIGURE 1 Markov model schema. Health states are shown in circles, 
and possible transitions between health states are depicted by arrows. 
All patients enter the model in either the “On therapy – ZA strategy” 
or “On therapy – No ZA strategy” state and move to other health states 
according to transition probabilities. Only patients treated with ZA 
can transition into the “ONJ” state. Patients were subject to mortal-
ity in all states based on state-specific and age-adjusted background 
probabilities. ZA = zoledronic acid; ONJ = osteonecrosis of the jaw
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Costs and Utilities
The analysis took a direct health system payer perspective 
and considered the costs associated with administration 
of all adjuvant therapies, as well as the downstream costs 
of follow-up and breast cancer recurrence (Table ii). Up-
front costs were estimated based on local unit costs at the 
QEII Health Sciences Centre in Halifax, Nova Scotia. The 
costs of managing adverse effects, breast cancer follow-
up, and treatment of recurrent disease have previously 
been reported and were derived from the literature28,29. 
The average cost for management of osteonecrosis of the 
jaw during the first month was calculated assuming that 
all patients underwent conservative treatment and that a 
proportion also required surgical intervention. The cost 
of conservative treatment was estimated based on expert 
opinion, and the cost of surgical procedures was derived 
from the literature30. All costs were adjusted to 2014 Cana-
dian dollars using the Consumer Price Index (health care 
component)31. Utility weights for individual health states 
were multiplicative and derived from a published database 
(https://research.tufts-nemc.org/cear4/Default.aspx) and 
from the literature (Table ii)32.
Sensitivity Analyses
Cost-effectiveness acceptability curves generated through 
probabilistic sensitivity analyses are presented to illustrate 
the probability of a za strategy being cost-effective across 
a range of willingness-to-pay thresholds. Tables i and 
ii show the distribution and ranges of individual model 
parameters tested in the probabilistic sensitivity analy-
ses. One-way sensitivity analyses were also performed 
to determine the effect of individual model parameters 
and assumptions on outcomes. The latter analyses in-
cluded scenarios in which za dfs and fracture benefits 
were individually eliminated, and a scenario in which za 
was dosed using the less-frequent abcsg-12 schedule13. 
Finally, although adjuvant ovarian suppression is not 
routine practice in our jurisdiction33, the primary analy-
sis assumed that adjuvant treatment for premenopausal 
women included ovarian suppression using an luteinizing-
hormone releasing-hormone agonist in both the za and 
no-za strategies. Another scenario was therefore included 
in which ovarian suppression was administered only in the 
za strategy. The remaining one-way sensitivity analyses 
are described in the Results section.
TABLE I Key model parameters
Parameter Distribution Point estimate Standard deviation Reference
Natural history
Risk of relapsea
Induced menopause Nonparametric 31.6% 0.5 EBCTCG, 20051
Natural menopause
Tamoxifen Nonparametric 30.5% 0.5 EBCTCG, 20051
Aromatase inhibitor Nonparametric 26.5% 0.7 EBCTCG, 20051
Sequential combinations Nonparametric 27.5% 0.5 EBCTCG, 20051
Distant relapse survival Poisson 21 Months 6 Hillner20
Fracture risk
Induced menopause Beta 2% 0.6 Gnant et al., 200913
Natural menopause
Tamoxifen Beta 4% 0.3 Baum et al., 200321
Howell et al., 200522
Aromatase inhibitor Beta 6% 0.3 Coombes et al., 200423
Goss et al., 200524
Zoledronic acid
Hazard ratio for DFS Beta 0.71 0.01 Wong et al., 20126
Hazard ratio for fracture
Induced menopause Beta 0.71 0.07 Gnant et al., 200913
Natural menopause Beta 0.65 0.07 Wong et al., 20126
Osteonecrosis of the jaw
Risk Beta 1.6% 0.3 Rathbone et al., 201318
Resolution rate Beta 35% 9 Rathbone et al., 201318
a Calculated from a uniform risk of relapse, with application of the benefit from each individual endocrine therapy.
EBCTCG = Early Breast Cancer Trialists’ Collaborative Group; DFS = disease-free survival.
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RESULTS
Table iv shows the per-patient cumulative costs and qaly 
gains in each cohort. Relative to the no-za strategy, adju-
vant za was associated with incremental costs and qaly 
gains in both the induced and natural menopause cohorts. 
In the induced menopause group, za was associated with 
a per-patient incremental cost of $7,825 [95% confidence 
interval (ci): $6,875 to $8,554] and 0.46 qalys gained (95% 
ci: 0.25 to 0.64 qalys gained), leading to an icur of $17,007 
(95% ci: $10,742 to $34,216) per qaly gained. In the natural 
menopause group, za was associated with a per-patient 
incremental cost of $7,789 (95% ci: $6,792 to $8,342) and 
0.34 qalys gained (95% ci: 0.20 to 0.49 qalys gained), lead-
ing to an icur of $23,093 (95% ci: $13,861 to $41,710) per 
qaly gained.
The cost-effectiveness acceptability curves suggested 
that the probability of adjuvant za being a cost-effective 
strategy relative to no-za at a threshold of $100,000 per 
qaly gained was 100% in both the induced and the natural 
menopause groups (Figure 2).
Figure 3 shows the one-way sensitivity analyses, 
which demonstrated that the cu of za was most sensitive 
to changes in its dfs benefit, dosing schedule (azure vs. 
abcsg-12), and elimination of adjuvant ovarian suppres-
sion in patients treated on the no-za strategy. Overall, the 
cu results were robust to reasonable ranges of uncertain-
ties. A scenario in which the za dfs benefit was eliminated 
(leaving only a fracture benefit) showed icurs of $102,169 
and $117,066 per qaly gained in the induced and natural 
menopause groups respectively. When the less-frequent 
dosing schedule from abcsg-12 was considered, the icurs 
TABLE II Model costs and utilities
Parameter Point estimate Standard deviation Duration Reference
Cost (dollars)a
Zoledronic acid (per dose) 543 136 5 Years QEII HSCb
LHRH agonist (per year) 3,150 788 3 Years QEII HSCb
Tamoxifen (per month) 11 3 5 Years QEII HSCb
AI (per month) 161 40 5 Years QEII HSCb
Fracture 6,484 1,621 — 29
Osteonecrosis of the jaw
First month 2,045 511 1 Month 30
Subsequent months 100 25 Variable —
Follow-up
Years 1–2 61 $15 2 Years 28
Subsequent years 38 $9 Variable 28
Distant relapse $37,700 1,724 21 Months 28
Local relapse $12,344 1,756 4 Months 28
Utilitiesc
Zoledronic acid 0.99 0.00 5 Years —
Endocrine therapies 0.95 0.01 5 Years 32
Fracture
Acute phase 0.80 0.02 1 Year 32
Chronic phase 0.98 0.00 Life 32
Osteonecrosis of the jaw 0.67 0.09 Variable 33
Disease-free 0.95 0.00 Life 32
Distant relapse 0.60 0.04 21 Months 32
Local relapse
First 0.70 0.03 4 Months 32
Second 0.50 0.05 4 Months 32
Treated local relapse 0.85 0.01 Life 32
Death 0.00 — — 32
a  In probabilistic sensitivity analysis, all costs were assumed to have log-normal distribution.
b  Derived from local unit costs at the QEII Health Sciences Centre (QEII HSC).
c  In probabilistic sensitivity analysis, all utility weights were assumed to have 1 log-normal distribution.
LHRH = luteinizing-hormone releasing-hormone; AI = aromatase inhibitor.
COST–UTILITY OF ADJUVANT ZOLEDRONIC ACID, Lamond et al.
e250 Current Oncology, Vol. 22, No. 4, August 2015 © 2015 Multimed Inc.
associated with adjuvant za were $3,899 and $5,506 per 
qaly gained in the induced and natural menopause groups 
respectively13. In a one-way sensitivity analysis in which 
ovarian suppression was administered only in the za strat-
egy, adjuvant za remained cost-effective, with an icur of 
$35,139 per qaly gained.
DISCUSSION
Pharmacoeconomic evaluations are important consider-
ations in the assessment of novel medical therapeutics and 
novel indications for established interventions34,35. Our cu 
evaluation suggests that adjuvant za is an economically 
favourable therapy in women with early-stage endocrine-
sensitive breast cancer and lle. The icurs of $17,007 and 
$23,093 per qaly gained in the primary analysis are con-
sidered “highly cost-effective” by the World Health Orga-
nization and are well within the commonly cited North 
American threshold of $100,00036–38.
The present pharmacoeconomic study is the first to 
consider both the fracture prevention and dfs benefits as-
sociated with adjuvant za. Our results accord with the lim-
ited data published to date, including two industry-funded 
cu analyses39,40. Logman et al.39 performed a cu analysis 
of upfront and delayed za strategies for the prevention of 
adjuvant aromatase inhibitor–induced bone loss among 
postmenopausal women with breast cancer. Treatment 
with za consisted of 4 mg intravenous infusions every 6 
months for up to 5 years during therapy with adjuvant 
aromatase inhibitor. The study took the perspective of the 
United Kingdom’s National Health Service and was based 
on interim results from the zo-fast study, considering only 
the fracture benefit of adjuvant za41. Compared with adju-
vant treatment omitting za, upfront and delayed za resulted 
in icurs of £21,973 and £16,069 per qaly gained—both 
considered “highly acceptable”39. Lux et al.40 published a 
second cu analysis of adjuvant za from the perspective of 
the German health care system. That study was based on 
the za dosing and results from abcsg-12 and considered 
only the dfs benefit13. The results suggested that adjuvant 
za was less costly and more effective (that is, dominant) 
when incorporated into adjuvant treatment including 
ovarian suppression in women with endocrine-sensitive 
breast cancer. These industry-sponsored studies used 
efficacy data from single trials39,40; by contrast, our study 
used pooled efficacy results from all trials of adjuvant za 
in the relevant setting.
Our study has several limitations that are partly a 
result of the significant methodologic heterogeneity of the 
adjuvant za trials. Where possible, those limitations were 
addressed in specific one-way sensitivity analyses. In the 
primary analysis, the hazard ratio for dfs with the use of 
adjuvant za was taken from a pooled efficacy analysis of 
phase iii clinical trials. However, uncertainty about the true 
breast cancer recurrence benefit of adjuvant za remains, 
and in our study, the za cu was most sensitive to changes 
in that parameter. In the scenario in which the za dfs 
benefit was eliminated entirely, the resultant icurs rose 
above commonly accepted thresholds. That observation 
suggests that, for adjuvant za to be cost-effective, it must 
provide some improvement in dfs.
TABLE III Primary analysis model assumptions
Chemotherapy, endocrine therapy, and radiation treatment were 
similar for both strategiesa.
Treatment and survival after relapse were similar for both strategiesa.
Nonparametric breast cancer recurrence rates were derived from 
Early Breast Cancer Trialists’ Collaborative Group data1.
The ratio of local to distant relapse was 1:2a.
Locoregional relapse and new contralateral cancers were combined 
as local relapsea.
Patients with local relapse were treated for 4 months, and then 
entered the treated local relapse statea.
Patients with local relapse were at risk of synchronous distant 
relapse and had double the risk of subsequent relapse eventsa.
The instant rate of distant relapse in patients with local relapse was 
20%.
Patients could experience only two local relapses. Subsequent 
relapses were distanta.
Patients with distant relapses had a median survival of 21 months20.
Patients could transition into the death state from any other state 
based on state-specific and background age-adjusted mortality 
probabilities19.
Adjuvant endocrine therapy in the naturally menopausal cohort 
included 40% aromatase inhibitor alone, 20% tamoxifen alone, and 
40% sequential combination strategiesb.
Adjuvant luteinizing-hormone releasing-hormone agonist therapy 
consisted of leuprolide 45 mg by subcutaneous injection every 6 
monthsb.
The utility penalty associated with zoledronic acid was calculated 
as one fifth that of endocrine therapyb.
Patients could transition into the osteonecrosis of the jaw state only 
during zoledronic acid treatmentb.
Osteonecrosis of the jaw resolved in 35% of affected patients after 
a median duration of 803 days18.
The fracture state included acute and chronic phases with different 
costs, utilities, and durationsa.
a Per our previous work26,27.
b Expert opinion.
TABLE IV Cumulative results
Cohort Zoledronic
acid strategy
Cumulative
Cost
($)
QALYs
gained
Induced menopause No 26,606 12.4
Yes 34,431 12.9
Natural menopause No 21,448 10.9
Yes 29,238 11.3
QALY = quality-adjusted life-year.
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Beyond those specific limitations, our hypothetical 
economic modelling study depends on multiple assump-
tions. Our probabilistic sensitivity analyses attempted to 
control for all possible uncertainties in the assumptions, 
and those analyses showed our results to be robust to 
reasonable changes in the model parameters. In the end, 
the cu results depend on model input and are, therefore, 
jurisdiction-specific. The za drug acquisition cost used 
FIGURE 3 Results of the one-way sensitivity analysis. The y axis shows the parameters and values tested in the one-way sensitivity analysis; the 
x axis reflects the resultant change in incremental cost-utility ratio (ICUR) in Canadian dollars per quality-adjusted life-year (QALY) gained (primary 
analysis results). Results are shown for the induced and natural menopause groups separately. DFS = disease-free survival; HR = hazard ratio; ZA = 
zoledronic acid; LHRH = luteinizing-hormone releasing-hormone; TAM = tamoxifen; AI = aromatase inhibitor.
FIGURE 2 Cost-effectiveness acceptability curves. The x axis shows the willingness-to-pay per quality-adjusted life-year (QALY) gained in 
Canadian dollars, and the y axis shows the probability that the strategy of therapy with zoledronic acid is cost-effective. The likelihood that that 
strategy is cost-effective at various willingness-to-pay thresholds is shown for both the induced and the natural menopause groups, based on 
probabilistic sensitivity analysis.
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in the analysis could change in future when generic za 
becomes available. As that change occurs, the cu of ad-
juvant za will become more favourable.
CONCLUSIONS
Compared with a no-za strategy of endocrine therapy, a 
strategy of adjuvant za plus endocrine therapy is associ-
ated with increased costs and qaly gains in women with 
early-stage endocrine-sensitive breast cancer and lle. 
The resultant icurs are considered highly cost-effective 
and would likely remain cost-effective even if the current 
evidence overestimates the dfs benefit of adjuvant za in 
the relevant setting36. It therefore appears that, economi-
cally, adjuvant za offers good value for money, further 
supporting its incorporation into routine clinical care 
for women with early-stage endocrine-sensitive breast 
cancer and lle.
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